Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. Show more

Location: 126 East Lincoln Avenue, Rahway, NJ, 07065, United States | Website: https://www.merck.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

199B

52 Wk Range

$73.31 - $114.79

Previous Close

$79.67

Open

$79.78

Volume

14,885,642

Day Range

$77.58 - $79.88

Enterprise Value

225.8B

Cash

8.622B

Avg Qtr Burn

N/A

Insider Ownership

0.07%

Institutional Own.

80.58%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

GARDASIL 9 Details
Human Papillomavirus 9-valent Vaccine, Human papillomavirus

Approved

Update

Approved

Update

KEYTRUDA Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Update

KEYTRUDA+ chemotherapy Details
Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma

Approved

Update

KEYTRUDA in comb w/chemotherapy Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

ENFLONSIA (clesrovimab-cfor) Details
Respiratory syncytial virus

Approved

Quarterly sales

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer

Approved

Quarterly sales

Clesrovimab (MK-1654) Details
Respiratory syncytial virus

Approved

Quarterly sales

KEYTRUDA® (pembrolizumab) Details
Head and neck squamous cell carcinoma

Approved

Quarterly sales

KEYTRUDA+ chemotherapy Details
Cancer, Biliary Tract Cancer

Approved

Quarterly sales

KEYTRUDA+ trastuzumab+ chemotherapy Details
Gastric cancer, Cancer, Gastroesophageal adenocarcinomas

Approved

Quarterly sales

CAPVAXIVE (V116) Details
Pneumococcal Conjugate Vaccine

Approved

Quarterly sales

Approved

Quarterly sales

PREVYMIS™ (letermovir) Details
Cytomegalovirus, Viral infection

Approved

Quarterly sales

KEYTRUDA + chemotherapy Details
Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

Approved

Quarterly sales

WINREVAIR™ (sotatercept-csrk) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

Approved

Quarterly sales

WELIREG® (belzutifan) Details
Renal cell carcinoma, von Hippel-Lindau, Cancer, Hemangioblastoma, Pancreatic neuroendocrine tumors

Approved

Quarterly sales

Approved

Quarterly sales

LYNPARZA(olaparib) + abi/pred Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

WELIREG® (belzutifan) Details
Pheochromocytoma , Paraganglioma

Approved

Quarterly sales

KEYTRUDA +carboplatin + paclitaxel Details
Cancer, Solid tumor/s, Carcinoma , Endometrial cancer

Approved

Quarterly sales

KEYTRUDA (pembrolizumab) injection Details
Gastric cancer, Gastroesophageal adenocarcinomas

PDUFA

Approval decision

Doravirine / Islatravir (DOR/ISL) Details
Virologically Suppressed HIV-1 Infection

PDUFA

Approval decision

WINREVAIR™ (sotatercept-csrk) Details
Pulmonary arterial hypertension

PDUFA

Approval decision

NDA

FDA meeting

MK-1084 +/- KEYTRUDA® Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Phase 3

Data readout

Tulisokibart (MK-7240) (PRA023) (Anti-TL1A mAb) Details
Irritable bowel syndrome, Crohns disease, Ulcerative colitis

Phase 3

Data readout

KEYTRUDA+pemetrexed Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Ifinatamab Deruxtecan (I-DXd) Details
Pretreated Metastatic Castration-Resistant Prostate Cancer

Phase 3

Data readout

LAGEVRIO™ (molnupiravir) Details
Viral infection, COVID-19

Phase 3

Data readout

Ifinatamab Deruxtecan (I-DXd) Details
Esophageal Squamous Cell Carcinoma

Phase 3

Data readout

Ifinatamab Deruxtecan (I-DXd) Details
Small cell lung cancer, Cancer

Phase 3

Data readout

MK-2870 Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Nemtabrutinib Details
Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Phase 3

Data readout

MK-5684 (ODM-208) Details
Cancer, Castration-resistant prostate cancer

Phase 3

Data readout

Bomedemstat Details
Thrombocythemia

Phase 3

Data readout

V181 Details
Dengue Vaccine

Phase 3

Data readout

Bomedemstat Details
Thrombocytopenia

Phase 3

Data readout

Phase 3

Data readout

Patritumab deruxtecan (HER3-DXd) Details
Non-small cell lung carcinoma

Phase 3

Data readout

KEYTRUDA Details
Cancer, Solid tumor/s, Urothelial carcinoma

Phase 3

Update

Enlicitide Decanoate (Previously MK-0616) Details
Cardiovascular disease , Hypercholesterolemia

Phase 3

Update

KEYTRUDA + LENVIMA Details
Cancer, Renal cell carcinoma

Phase 3

Update

Phase 3

Update

Phase 3

Update

MK-1084 + cetuximab + mFOLFOX6 Details
unresectable or metastatic CRC

Phase 3

Update

Zilovertamab (MK-2140) Details
Previously Untreated Diffuse large B cell lymphoma

Phase 3

Update

KEYTRUDA Details
Cancer, Renal cell carcinoma

Phase 3

Update

KEYTRUDA Details
Solid tumor/s, Cancer, Triple-negative breast cancer , Breast cancer

Phase 3

Update

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Carcinoma , Endometrial cancer

Phase 3

Update

KEYTRUDA + favezelimab Details
Cancer, Metastatic colorectal cancer

Phase 3

Update

KEYTRUDA® plus paclitaxel +/- bevacizumab Details
Platinum-Resistant Recurrent Ovarian Cancer

Phase 3

Update

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Non-small cell lung carcinoma

Phase 3

Update

KEYTRUDA + LENVIMA in comb w/TACE Details
Cancer, Hepatocellular carcinoma

Phase 3

Update

KEYTRUDA Details
Cancer, Solid tumor/s, ER+/HER2- breast cancer

Phase 3

Update

Phase 3

Initiation

Phase 3

Initiation

Raludotatug Deruxtecan Details
Platinum-resistant ovarian cancer, Cancer

Phase 2/3

Data readout

Restoret (MK-3000, formerly EYE103) Details
Eye disease , Diabetic macular edema

Phase 2/3

Data readout

Zilovertamab (MK-2140) Details
r/r Diffuse large B cell lymphoma

Phase 2/3

Update

Efinopegdutide (MK-6024) Details
Non-Alcoholic Fatty Liver Disease, Liver disease

Phase 2b

Initiation

Phase 2

Data readout

PRA023 (Anti-TL1A mAb) Details
Autoimmune disease, Systemic sclerosis

Phase 2

Update

Ifinatamab Deruxtecan (I-DXd) Details
Small cell lung cancer, Cancer

Phase 2

Update

Belzutifan + cabozantinib Details
Cancer, Renal cell carcinoma

Phase 2

Update

PRA023 (Anti-TL1A mAb) Details
Systemic sclerosis, Autoimmune disease

Phase 2

Update

HPN328 (DLL3) +/- atezolizumab Details
Cancer, Small cell lung cancer, Solid tumor/s

Phase 1/2

Update

MK-1084 Details
Colorectal cancer, Non-small cell lung carcinoma

Phase 1

Update

PRA052 Details
Inflammatory bowel disease

Phase 1

Update

HPN217 (BCMA) Details
Multiple myeloma

Phase 1

Update

KEYTRUDA + LENVIMA Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Failed

Discontinued